title: Effective in vivo induction of lymphokine-activated killer (LAK) cells by pretreatment with a streptococcal preparation, OK-432.
abstract: Effects of a streptococcal preparation, OK-432, on precursors of lymphokine-activated killer (LAK) cells were observed in vivo. Total number of splenocytes and the ratio of asGM1+ cells increased gradually after i.v. administration of OK-432, reaching their peaks at 3 to 4 days. It was found that asGM1+ cells were nonadherent and large in size. There were little differences in the ratios of Thy-1+, Lyt-2+, and L3T4+ cells before and after OK-432 treatment. Mice were injected i.p. with recombinant interleukin 2 (rIL-2) at a dose of 5 x 10(4) U per mouse 4 days after OK-432 administration and LAK activity in their splenocytes was examined using natural killer (NK) resistant EL-4 target cells. Splenocytes in mice treated with both OK-432 and rIL-2 showed higher LAK activity than those in mice treated with rIL-2 alone. In vivo treatment with anti asGM1 antibody prior to rIL-2 injection abolished completely such augmentation of LAK activity in OK-432 treated mice. These results demonstrated that asGM1+ LAK precursor cells induced by OK-432 were effectively differentiated into LAK cells by rIL-2.
authors.affiliation: First Department of Surgery, Medical College of Oita, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Shimoda
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: K
authors.initials: K
authors.lastname: Nomoto
mesh_terms: D000818:Animals; D000906:Antibodies / Q000008:administration & dosage; D005260:Female; D005434:Flow Cytometry; D005453:Fluorescence; D005677:G(M1) Ganglioside / Q000276:immunology; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects* / Q000276:immunology; D051379:Mice; D008809:Mice, Inbred C3H; D010844:Picibanil / Q000493:pharmacokinetics / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D013154:Spleen / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D013997:Time Factors
chemical_list: D000906:Antibodies; D007376:Interleukin-2; D011994:Recombinant Proteins; D005677:G(M1) Ganglioside; D010844:Picibanil; C018835:asialo GM1 ganglioside